American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal is a 501(c)(6) organization based in Philadelphia, Pennsylvania, registered in 1980, with $2,328,197 in FY2024 revenue. CharityIndex grades it B.
Revenue (FY2024)
$2.3M
▼ 6.0% vs prior year
Expenses (FY2024)
$2.5M
Net assets
$7.5M
Employees
—
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. Not scored for American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal— this filing type doesn't report it, and the rating simply skips it (never counts it against the organization). See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal: 36 mo reserves · -7% margin earns a B+ on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. Not scored for American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal— this filing type doesn't report it, and the rating simply skips it (never counts it against the organization). See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal: 2 of 5 disclosure signals earns a C on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Revenue grew from $1.9M (FY2013) to $2.3M (FY2024) across 12 reported years.
Financial snapshot
Operating margin
-6.7%
Spent more than it raised in the latest fiscal year.
Total assets
$8.1M
Total liabilities
$658K
Net assets
$7.5M
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $2,328,197▼6.0% | $2,484,733▲10.5% | $7,472,370▲3.2% | $8,130,273▲1.9% | 990 |
| 2023 | $2,476,194▼33.7% | $2,249,168▲13.4% | $7,243,581▲15.0% | $7,978,586▲13.0% | 990 |
| 2022 | $3,732,912▲66.0% | $1,983,099▲10.6% | $6,301,109▼13.9% | $7,060,203▼6.6% | 990 |
| 2021 | $2,248,891▲33.7% | $1,793,349▲0.5% | $7,320,741▲18.1% | $7,560,315▲17.3% | 990 |
| 2020 | $1,682,502▼13.1% | $1,784,456▼10.1% | $6,196,594▲8.0% | $6,445,171▲7.7% | 990 |
| 2019 | $1,935,763▼7.5% | $1,984,294▲3.2% | $5,736,111▲13.5% | $5,986,455▲13.2% | 990 |
| 2018 | $2,092,093▲36.7% | $1,922,366▲6.2% | $5,055,866▼4.9% | $5,290,155▼5.3% | 990 |
| 2017 | $1,530,243▼11.9% | $1,809,379▲7.9% | $5,319,145▲0.5% | $5,588,532▲1.0% | 990 |
| 2016 | $1,737,318▼9.5% | $1,676,698▼1.7% | $5,292,634▲2.1% | $5,532,356▲3.6% | 990 |
| 2015 | $1,919,640▲20.8% | $1,704,888▲11.7% | $5,185,291▲2.5% | $5,339,925▲3.2% | 990 |
| 2014 | $1,589,523▼17.2% | $1,526,040▲1.7% | $5,058,975▲7.8% | $5,173,263▲7.1% | 990 |
| 2013 | $1,919,921 | $1,501,085▲5.2% | $4,693,318▲21.9% | $4,828,938▲22.2% | 990 |
| 2012 | — | $1,427,371▼1.9% | $3,850,244▲6.4% | $3,952,337▲6.1% | 990 |
| 2011 | — | $1,454,825 | $3,617,758 | $3,723,623 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Explore more
Data for American Board of Allergy & Immun A Cons Board of Am Bd Int Med Etal (EIN 23-7171573) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.